Carregant...
The TLR7 agonist Imiquimod promote the immunogenicity of msenchymal stem cells
BACKGROUND: Mesenchymal stem cells (MSCs) are considered the best candidate in stem cells therapy due to their multipotent differentiation ability, low expression of co-stimulatory molecules (CD80, CD86, CD34 and HLA-II) and immunosuppression effects on in vivo immune responses. MSCs were now widely...
Guardat en:
| Publicat a: | Biol Res |
|---|---|
| Autors principals: | , , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BioMed Central
2015
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4363195/ https://ncbi.nlm.nih.gov/pubmed/25654296 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/0717-6287-48-6 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|